{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease", "query": { "condition": "Minimal Residual Disease" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 183, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T08:13:21.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06902272", "title": "ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay", "type": "DIAGNOSTIC_TEST" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Platinum Doublet Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-06-11", "completion_date": "2029-06-11", "has_results": false, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06902272" }, { "nct_id": "NCT06693830", "title": "ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma", "Lymphoma, B-Cell", "Diffuse Large B Cell Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High-grade B-cell Lymphoma" ], "interventions": [ { "name": "Phased Variant Enrichment and Detection Sequencing (PhasED-seq)", "type": "DEVICE" }, { "name": "Standard of Care Treatment", "type": "OTHER" }, { "name": "De-escalated Treatment", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Hua-Jay J Cherng, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-12-11", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06693830" }, { "nct_id": "NCT05554393", "title": "Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 153, "start_date": "2024-09-13", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 167, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 136 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05554393" }, { "nct_id": "NCT06974786", "title": "Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma, Newly Diagnosed", "Multiple Myeloma (MM)" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "autologous stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 100, "start_date": "2025-08-08", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974786" }, { "nct_id": "NCT05307939", "title": "A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV", "Oropharynx Cancer", "HPV-Related Carcinoma", "HPV-Related Malignancy", "HPV Positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "HPV ctDNA Assay", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Studies", "type": "DIAGNOSTIC_TEST" }, { "name": "EORTC QLQ H&N 35 and C30", "type": "BEHAVIORAL" }, { "name": "MDADI-HN", "type": "BEHAVIORAL" }, { "name": "COST-FACIT", "type": "BEHAVIORAL" }, { "name": "Intensity-Modulated Radiation Therapy (Arm A)", "type": "RADIATION" }, { "name": "Chemoradiation (Arm B)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "BEHAVIORAL", "RADIATION", "COMBINATION_PRODUCT" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-03-24", "completion_date": "2027-03-24", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 8, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05307939" }, { "nct_id": "NCT02767934", "title": "Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "Minimal Residual Disease", "Recurrent Acute Lymphoblastic Leukemia", "T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-01-13", "completion_date": "2019-12-17", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02767934" }, { "nct_id": "NCT06230185", "title": "CtDNA Based MRD Testing for NAC Monitoring in TNBC", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "TNBC - Triple-Negative Breast Cancer", "Minimal Residual Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Personalis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 422, "start_date": "2023-11-09", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 14, "location_summary": "Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06230185" }, { "nct_id": "NCT06744296", "title": "Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Blood Draws and Tissue Sample(s)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2025-02-03", "completion_date": "2029-01-06", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06744296" }, { "nct_id": "NCT03441061", "title": "Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia", "Recurrent B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-02-15", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441061" }, { "nct_id": "NCT06878131", "title": "Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Colorectal Cancer", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-04-18", "completion_date": "2028-12-22", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T08:13:21.521Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06878131" } ] }